EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A BRILLIANT-BRCA study: residual breast tissue after mastectomy and reconstruction

Orit Kaidar-Person, Renata Faermann, Dor Polikar, Kfir Cohen, Rinat Bernstein-Molho, Monica Morrow, Liesbeth Jorinne Boersma, Birgitte Vrou Offersen, Philip Poortmans, Miri Sklair-Levy, Debbie Anaby

Breast Cancer Research and Treatment · 2024

DOI: 10.1007/s10549-024-07425-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Breast Cancer Research and Treatment, 2024. Verfasst von Orit Kaidar-Person und 10 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Faculty of Medical & Health Sciences, Tel-Aviv University, Tel-Aviv, Israel. orit.kaidarperson@sheba.health.gov.il. Hauptthemen laut MEDLINE: Breast Neoplasms, Magnetic Resonance Imaging, Mastectomy, Mammaplasty. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Conquer Cancer Foundation, Tel Aviv University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Different types of mastectomies leave different amounts of residual breast tissue. The significance of the residual breast volume (RBV) is not clear. Therefore, we developed an MRI tool that allows to easily assess the RBV. In this study we evaluated factors associated with RBV after skin or nipple sparing mastectomy (SSM/NSM) in breast cancer BRCA pathogenic variant (PV) carriers who underwent both therapeutic and risk reducing SSM/NSM and its relation to breast cancer outcomes using an innovative MRI-based tool.

Methods

Data of breast cancer BRCA PV who were treated between 2006 and 2020 were retrieved from of the oncogenetics unit databases. Only patients who underwent SSM/NSM and had a postoperative breast MRI available for analysis were included. Data collected included demographics, clinicopathological features, and outcomes. The MRI tool was developed by a breast cancer imaging laboratory. A logistic regression test and 95% confidence interval (CI) were used to assess the associated risk of increased RBV. A forward stepwise linear regression was used to correlate tumour-patient specific factors and RBV, and a Kaplan–Meier curve to show the probability of locoregional relapse.

Results

A total of 84 patients undergoing 89 mastectomies were included. At a median follow-up of 98 months, 5 local, 2 regional, and 4 distant recurrences were observed. RBV was not significantly related with breast cancer outcomes ( p value = NS). A higher body mass index (BMI) was associated with a higher RBV ( p < 0.0001). A larger number of involved axillary nodes was associated with a smaller RBV ( p = 0.025). The RBV on the risk-reducing mastectomy side was significantly higher compared to the breast cancer side ( p value = 0.007). Local recurrences occurred in the vicinity of the primary tumour.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsMagnetic Resonance ImagingMastectomyMammaplastyHumansFemaleMiddle AgedAdultNeoplasm Recurrence, LocalAgedBreastBRCA2 ProteinFollow-Up StudiesBRCA1 ProteinRetrospective Studies

Stichwörter der Autor:innen

Breast tissueMRIMastectomyNipple sparingResidual breastRisk reducing mastectomySkin sparing

Substanzen

BRCA2 ProteinBRCA1 ProteinBRCA1 protein, human

Autor:innen und Institutionen

  • School of Medicine, Faculty of Medical & Health Sciences, Tel-Aviv University, Tel-Aviv, Israel. orit.kaidarperson@sheba.health.gov.il.
  • Breast Radiation Unit, The Jusidman Cancer Center, Chaim Sheba Medical Center, Tel-Hashomer, Ramat-Gan, Israel. orit.kaidarperson@sheba.health.gov.il.
  • GROW-School for Oncology and Reproduction, Maastricht University, Maastricht, The Netherlands. orit.kaidarperson@sheba.health.gov.il.
  • School of Medicine, Faculty of Medical & Health Sciences, Tel-Aviv University, Tel-Aviv, Israel.
  • The Merav High-Risk Clinic - Chaim Sheba Medical Center, Tel-Hashomer, Ramat-Gan, Israel.
  • Department of Diagnostic Imaging, Sheba Medical Center, Tel-Hashomer, Ramat-Gan, Israel.

Förderung

  • NCI NIH HHS
  • Conquer Cancer Foundation
  • Tel Aviv University

Zitieren

APA

Kaidar-Person, O., Faermann, R., Polikar, D., Cohen, K., Bernstein-Molho, R., Morrow, M., Boersma, L. J., Offersen, B. V., Poortmans, P., Sklair-Levy, M., & Anaby, D. (2024). A BRILLIANT-BRCA study: residual breast tissue after mastectomy and reconstruction. Breast Cancer Research and Treatment. https://doi.org/10.1007/s10549-024-07425-4

Vancouver

Kaidar-Person O, Faermann R, Polikar D, Cohen K, Bernstein-Molho R, Morrow M, et al. A BRILLIANT-BRCA study: residual breast tissue after mastectomy and reconstruction. Breast Cancer Research and Treatment. 2024. doi:10.1007/s10549-024-07425-4

BibTeX
@article{KaidarPerson2024,
  author = {Kaidar-Person, Orit and Faermann, Renata and Polikar, Dor and Cohen, Kfir and Bernstein-Molho, Rinat and Morrow, Monica and Boersma, Liesbeth Jorinne and Offersen, Birgitte Vrou and Poortmans, Philip and Sklair-Levy, Miri and Anaby, Debbie},
  title = {A BRILLIANT-BRCA study: residual breast tissue after mastectomy and reconstruction},
  journal = {Breast Cancer Research and Treatment},
  year = {2024},
  doi = {10.1007/s10549-024-07425-4}
}
Kostenlos starten →